Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017;9:448–51. https://doi.org/10.21037/jtd.2017.02.75.

Article  PubMed  PubMed Central  Google Scholar 

Vainshelboim B, Müller J, Lima RM, Nead KT, Chester C, Chan K, et al. Cardiorespiratory fitness, physical activity and cancer mortality in men. Prev Med. 2017;100:89–94. https://doi.org/10.1016/j.ypmed.2017.04.014.

Article  PubMed  Google Scholar 

Mattiuzzi C, Lippi G. Current Cancer Epidemiology. J Epidemiol Glob Health. 2019;9:217–22. https://doi.org/10.2991/jegh.k.191008.001.

Article  PubMed  PubMed Central  Google Scholar 

Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharm. 2018;834:188–96. https://doi.org/10.1016/j.ejphar.2018.07.034.

Article  CAS  Google Scholar 

Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet. 2018;14:e1007362. https://doi.org/10.1371/journal.pgen.1007362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17:75–90. https://doi.org/10.1038/s41571-019-0266-5.

Article  PubMed  Google Scholar 

Villanueva L, Álvarez-Errico D, Esteller M. The Contribution of Epigenetics to Cancer Immunotherapy. Trends Immunol. 2020;41:676–91. https://doi.org/10.1016/j.it.2020.06.002.

Article  CAS  PubMed  Google Scholar 

Demetriadou C, Koufaris C, Kirmizis A. Histone N-alpha terminal modifications: genome regulation at the tip of the tail. Epigenetics Chromatin. 2020;13:29. https://doi.org/10.1186/s13072-020-00352-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020;19:776–800. https://doi.org/10.1038/s41573-020-0077-5.

Article  CAS  PubMed  Google Scholar 

Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem. 2004;93:57–67. https://doi.org/10.1002/jcb.20179.

Article  CAS  PubMed  Google Scholar 

Mottamal M, Zheng S, Huang T-L, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–41. https://doi.org/10.3390/molecules20033898.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Seto E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016;6:a026831. https://doi.org/10.1101/cshperspect.a026831.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504. https://doi.org/10.1016/j.lfs.2021.119504.

Article  CAS  PubMed  Google Scholar 

Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139–48. https://doi.org/10.1016/S1470-2045(08)70004-4.

Article  CAS  PubMed  Google Scholar 

Sudo T, Mimori K, Nishida N, Kogo R, Iwaya T, Tanaka F, et al. Histone deacetylase 1 expression in gastric cancer. Oncol Rep. 2011;26:777–82. https://doi.org/10.3892/or.2011.1361.

Article  CAS  PubMed  Google Scholar 

Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008;10:1021–7. https://doi.org/10.1593/neo.08474.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, et al. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis. 2015;6:e1657. https://doi.org/10.1038/cddis.2015.24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511–20. https://doi.org/10.4161/15592294.2014.983367.

Article  PubMed  PubMed Central  Google Scholar 

Was H, Krol SK, Rotili D, Mai A, Wojtas B, Kaminska B, et al. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clin Epigenetics. 2019;11:11. https://doi.org/10.1186/s13148-018-0598-5.

Article  PubMed  PubMed Central  Google Scholar 

Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, et al. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Philos). 2014;7:351–61. https://doi.org/10.1158/1940-6207.CAPR-13-0254.

Article  CAS  Google Scholar 

Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604–10. https://doi.org/10.1038/sj.bjc.6604199.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie H-J, Noh JH, Kim JK, Jung KH, Eun JW, Bae HJ, et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One. 2012;7:e34265. https://doi.org/10.1371/journal.pone.0034265.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blixt NC, Faulkner BK, Astleford K, Lelich R, Schering J, Spencer E, et al. Class II and IV HDACs function as inhibitors of osteoclast differentiation. PLoS One. 2017;12:e0185441. https://doi.org/10.1371/journal.pone.0185441.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, Zheng J-M, Chen J-K, Yan X-L, Chen H-M, Nong W-X, et al. Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1. Mol Med Rep. 2014;10:2045–50. https://doi.org/10.3892/mmr.2014.2395.

Article  CAS  PubMed  Google Scholar 

Hou F, Li D, Yu H, Kong Q. The mechanism and potential targets of class II HDACs in angiogenesis. J Cell Biochem. 2018;119:2999–6. https://doi.org/10.1002/jcb.26476.

Article  CAS  PubMed  Google Scholar 

Kumar V, Thakur JK, Prasad M. Histone acetylation dynamics regulating plant development and stress responses. Cell Mol Life Sci. 2021;78:4467–86. https://doi.org/10.1007/s00018-021-03794-x.

Article  CAS  PubMed  Google Scholar 

Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem. 2002;277:25748–55. https://doi.org/10.1074/jbc.M111871200.

Article  CAS  PubMed  Google Scholar 

Liu S-S, Wu F, Jin Y-M, Chang W-Q, Xu T-M. HDAC11: a rising star in epigenetics. Biomed Pharmacother. 2020;131:110607. https://doi.org/10.1016/j.biopha.2020.110607.

Article  CAS  PubMed  Google Scholar 

He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, et al. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). Eur J Med Chem. 2022;227:113946. https://doi.org/10.1016/j.ejmech.2021.113946.

Article  CAS  PubMed  Google Scholar 

Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84–90. https://doi.org/10.1038/nbt1272.

Article  CAS  PubMed  Google Scholar 

Yang LP. Romidepsin: in the treatment of T-cell lymphoma. Drugs. 2011;71:1469–80. https://doi.org/10.2165/11207660-000000000-00000.

Article  CAS  PubMed  Google Scholar 

Poole RM. Belinostat: first global approval. Drugs. 2014;74:1543–54. https://doi.org/10.1007/s40265-014-0275-8.

Article  CAS  PubMed  Google Scholar 

Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015;75:695–4. https://doi.org/10.1007/s40265-015-0403-0.

Article  CAS  PubMed